Abstract
BackgroundMyeloma survival has greatly increased over past decades. We investigated trends in survival over time in New Zealand by age, ethnicity, and geography and thus examined potential inequalities among these population subgroups.MethodsFrom data supplied by the New Zealand Ministry of Health, all new diagnoses of multiple myeloma (ICD-10 code C90) between 1990 and 2016 were extracted, as well as their matched mortality data. Cox’s proportional hazards regression and competing risks regression were used to estimate multivariable survival functions.ResultsBetween 1 January 1990 and 1 December 2015, 6642 myeloma cases were registered by the New Zealand Cancer Registry. Although survival from myeloma increased substantially from 1990–1994 to 2010–2015, 5-year survival was still only about 60% in 2010–2015. The greatest improvement in survival was for people aged 60–69 years at diagnosis. Using Cox’s proportional hazards regression, Māori showed an increased risk of myeloma death but this was predominantly due to differences in competing risks among ethnic groups. Competing risks analysis found the greatest improvement in myeloma survival in Pacific Islanders, and in 2010–2015 Māori had better survival than other ethnicities. Myeloma survival improved significantly over time in all regional health authorities but in all time periods the Central and Southern regions had significantly poorer survival than the Midland region.ConclusionsImprovements in myeloma survival have been unequal across subgroups and regions in New Zealand. Detailed information about utilization of chemotherapeutic agents and transplantation in New Zealand is not available. This information, as well as more detailed hematological data, is essential to further explore the relationships and reasons for differing myeloma survival in population subgroups of New Zealand.
Highlights
Myeloma survival has greatly increased over past decades
We aimed to investigate the change in survival from myeloma over time in New Zealand by age, ethnic group and geography and examine potential inequalities among these population groups
In New Zealand, between 1 January 1990 and 1 December 2015, 6642 diagnoses of myeloma were reported to the New Zealand Cancer Registry (NZCR) (Table 1)
Summary
Myeloma survival has greatly increased over past decades. Multiple myeloma (plasma cell myeloma) is a hematological cancer involving the proliferation of plasma cells within the bone marrow. Survival has greatly increased over the past few decades, . In 1996 the first study of high-dose chemotherapy combined with autologous stem cell transplantation that showed improved outcomes for myeloma patients was published [10]. Since this procedure has become the standard of care for over two decades [11]. Conditioning chemotherapy before transplantation has been predominantly melphalan in New Zealand and more recently some selected patients will have received tandem transplantation
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
